Recombinant Human FLT3LG/Flt3 Ligand Protein (His Tag)(Active)
SKU: PKSH031692-50
Recombinant Human FLT3LG/Flt3 Ligand Protein (His Tag)(Active)
SKU # | PKSH031692 |
Expression Host | Baculovirus-Insect Cells |
Description
Synonyms | FLT3LG, Flt3 Ligand, Flt3L, Fms-Felated Tyrosine Kinase 3 Ligand, SL Cytokine |
Species | Human |
Expression Host | Baculovirus-Insect Cells |
Sequence | Thr 27-Pro185 |
Accession | P49771-1 |
Calculated Molecular Weight | 20.2 kDa |
Observed Molecular Weight | 27 kDa |
Tag | N-His |
Bio-activity | Measured in a cell proliferation assay using BaF3 mouse pro-B cells transfected with mouse Flt-3. The ED50 for this effect is typically 2-11 ng/mL. |
Properties
Purity | > 95 % as determined by reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
Formulation | Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
Reconstitution | Please refer to the printed manual for detailed information. |
Background
FLT3L, also known as flt3 ligand, is a small molecule that acts as a growth factor that increases the number of immune cells by activating the hematopoietic progenitors. In vivo, FLT3L also induces the mobilization of the hematopoietic progenitors and stem cells. This may help the system to kill cancer cells. Dendritic cells (DCs) provide the key link between innate and adaptive immunity by recognizing pathogens and priming pathogen-specific immune responses. FLT3L controls the development of DCs and is particularly important for plasmacytoid DCs and CD8 -positive classical DCs and their CD103 -positive tissue counterparts.